Why Investors Should Care About Hepatitis C
Nick is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.
Hepatitis C, caused by the hepatitis C virus (HCV), is an infectious disease affecting the liver. An estimated 130 million-200 million people worldwide are infected with hepatitis C, and more than 350,000 people die every year from hepatitis C-related liver diseases.
HCV is the most common chronic blood-borne infection in the United States and the leading cause of liver transplants, according to the Centers for Disease Control and Prevention. There are at least six different subtypes of the hepatitis C virus, and each responds differently to treatment. On June 20, the U.S. Food and Drug Administration (FDA) approved a test that identifies the genotype of hepatitis C virus (HCV) that a patient is carrying. By using a sample of an infected patient’s blood plasma or serum, the Abbott RealTime HCV Genotype II can differentiate genotypes 1, 1a, 1b, 2, 3, 4, and 5. By knowing the type of HCV a person is infected with, more effective treatment can be given as different HCV genotypes respond differently to available drug therapies.
The Abbott RealTime HCV Genotype II test is manufactured by Abbott Molecular, owned by Abbott (NYSE: ABT). Abbott has a strong commitment with a long history to hepatitis and has developed the first commercial tests for detection of hepatitis B and tests for hepatitis A. After the separation of AbbVie (NYSE: ABBV), Abbott focuses more on the diagnostics segment. Fueled by strong revenue growth from point-of-care and core-lab units, the diagnostic segment reported a 4.4% increase in revenue in the last quarter.
The worldwide hepatitis C market is forecast to grow from $3.8 billion in 2011 to $14.5 billion in 2020, boosted by increase in diagnosis rates following an increase in screening, as well as the introduction of more effective and tolerable pipeline agents.
While careful screening is essential for the treatment to determine the most appropriate approach for the patient, traditional combination antiviral therapy with interferon and ribavirin still faces some challenges. More effective and better-tolerated drugs are needed. AbbVie and Gilead Sciences (NASDAQ: GILD) are racing to launch a new generation of all-oral hepatitis C drugs, whereas Gilead’s new drug can cure 95% of patients after eight weeks of therapy and AbbVie’s treatment delivered a slightly lower cure rate of 90% in a Phase II trial. Both drugs provide faster cures with less side effects, and the first drug to the market should quickly penetrate the estimated $20 billion market. For Gilead, the new drug is estimated to have annual sales of $6.03 billion by 2016, according to the analysts' estimates compiled by Bloomberg, whereas analysts are projecting $10.62 billion of total revenue for fiscal 2013. As for AbbVie, the new hepatitis C drugs could generate annual sales of $3 billion, as estimated by Morningstar analyst Damien Conover. Analysts currently are projecting total annual revenue of $18.48 billion for fiscal 2013 for AbbVie.
Unfortunately, another hepatitis C drug developed by Achillion Pharmaceuticals (NASDAQ: ACHN) suffered a major setback. On July 1, the U.S. FDA placed a clinical hold on its hepatitis C drug sovaprevir after elevations in liver enzymes were noted in an early-stage study of the drug's interaction with an HIV drug. Elevations in liver enzymes could be an indication of liver damage. Although the hold does not affect mid-stage study, the company may not recruit new subjects when the study is on hold. The new drug could potentially lose access to market for HIV patients and affect doctors’ decisions to prescribe. The company plans to provide more data from two drug-interaction studies and a safety analysis of continuing sovaprevir studies to the regulatory agency in six weeks to resolve the hold. Although the financial impact for the hold cannot be properly assessed yet, Achillion's share price plunged over 20% upon the release of this FDA hold.
For investors interested in profiting from the new hepatitis C drugs, both AbbVie and Gilead Sciences are sounding bet. For the long-term, Abbott will remain one of the best, solid investment targets when it comes to hepatitis C diagnosis.
The Motley Fool's chief investment officer has selected his No. 1 stock for this year. Find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2013." Just click here to access the report and find out the name of this under-the-radar company.
Nick Chiu has put position of Achillion Pharmaceuticals. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. Is this post wrong? Click here. Think you can do better? Join us and write your own!